Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenu archivé le 2024-06-18

Combatting Bacterial Resistance in Europe

Objectif

The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are around € 1.5 Billion per year in Europe, with an estimated 25,000 deaths (European Center for Disease prevention and Control/European Medicines Agency “time to react”). While the threat of antimicrobial resistance is growing, so are the challenges to bringing forward new therapeutic options for patients infected with resistant organisms. There is a need for a better understanding of how antimicrobial resistance is evolving globally, of what novel molecular mechanisms can be exploited as new forms of antimicrobial therapy and of how to more efficiently develop new treatments so they can be more rapidly brought to patients in need.
The over-arching concept of New Drugs for Bad Bugs (ND4BB) is to create an innovative public-private collaborative partnership that will positively impact all aspects of ARB through the discovery and development of novel agents for the treatment, prevention and management of patients with bacterial infections. COMBACTE is one of the first projects to be launched under this programme with the aim of developing a broad European network of fully capable and Good Clinical Practice (GCP) compliant clinical investigation sites to execute clinical trials enabling the registration of novel agents to be used in the treatment of patients with bacterial infections. The growth and application of the network will be supported with robust microbiologic surveillance data and clinical epidemiologic data. To reduce the time and or cost of clinical development, novel clinical trial designs will be outlined and supported through analysis of publically available and consortium-shared non-clinical and clinical data. In addition to executing the initial set of clinical trials, investigations of patient and pathogen-related biomarkers and the logistical and decision making impact of rapid diagnostics will be conducted.

Champ scientifique

Programme(s)

Thème(s)

Appel à propositions

IMI-JU-06-2012
Voir d’autres projets de cet appel

Régime de financement

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Coordinateur

ASTRAZENECA AB
Contribution de l’UE
Aucune donnée
Adresse
Vastra Maelarhamnen
151 85 Sodertaelje
Suède

Voir sur la carte
Région
Östra Sverige Stockholm Stockholms län
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Jörgen Jensen (Project Manager)
Chercheur principal
Hasan Jafri (Senior Director, Clinical Research and Development)
Liens
Coût total
Aucune donnée

Participants (38)

Partager cette page

Télécharger

Dernière mise à jour: 10 Février 2022

Mon livret

Permalink: https://cordis.europa.eu/project/id/115523/fr

European Union, 2024